Episode Highlights
0:04 Introduction
1:23 History of Ocuphire Pharma
3:50 Leading a small, high-functioning team
6:41 Magrath’s background
11:02 APX3330 for Diabetic Retinopathy
15:20 2024 Plans for Ocuphire
18:53 Addressing unmet needs
20:20 Outro
New Insight: A Look at APX3330 for Diabetic Retinopathy with George Magrath, MD
The latest episode of New Insight features a conversation with Ocuphire Pharma’s CEO on the company’s flagship retinal product and leading a small, but high-powered research team.
2023 was a remarkable year for ophthalmology, but the next year is already shaping up to be a productive, and forward-thinking, year for the specialty. As the treatment landscape continues to expand, based on strong outcomes from clinical trials and early data on innovative, novel therapies, the benefits will grow for both patients and clinicians.
The newest episode of New Insight with Veeral Sheth, MD features a conversation with Ocuphire Pharma’s chief executive officer and board member, George Magrath, MD, on the company’s history in ophthalmology, its recent therapeutic approval for mydriasis, and its lead product for diabetic retinopathy as the company shift to focus on retina.
Every episode of New Insight with Veeral Sheth, MD takes an in-depth look at the biggest news in ophthalmology and the behind-the-scenes work involved in eye care, with a rotation of guest experts involved in ophthalmic research, development, and clinical care.
In this episode, Sheth and Magrath discussed the history of Ocuphire Pharma and the company’s recent successes in ophthalmology, including the US Food and Drug Administration (FDA) approval of Phentolamine Ophthalmic Solution 0.75% (RYZUMVI™) for the treatment of pharmacologically-induced mydriasis.
The conversation then turned to Magrath’s background and journey across ophthalmology and beyond, before centering on the company’s flagship retinal product, APX3330 for diabetic retinopathy, and the small, but high-functioning team working behind the scenes. A recent end-of-phase 2 meeting with the FDA supported the advancement of APX3330, an oral inhibitor of the transcription factor regulator Ref-1, into phase 3 trials.
Sheth and Magrath wrapped up the episode with a discussion on Ocuphire’s plans for 2024, including preparations for the phase 3 clinical trial program, finding trial participants who would benefit the most from treatment, and addressing an unmet need for these patients.
Every episode of New Insight is available on HCPLive.com. Subscribe to our Youtube channel and listen on Spotify, Apple Podcasts, or the below player.
Please direct any podcast-related inquiries to show producer Connor Iapoce. Keep an eye out for more from New Insight!
Related Videos
Related Content
